When should practitioners order Babesia cePCR instead of serology?

Order cePCR when confirmation of active infection is needed, particularly in acute illness before antibody development, when serology is equivocal, or when distinguishing current from past infection. Serology is better for retrospective or chronic-phase diagnosis; the two are complementary.

Can a negative cePCR result exclude babesiosis?

No. A negative result does not exclude infection if the specimen was collected too early or late, during or after therapy, or if parasitaemia is below the detection threshold. Correlate with serology, blood-smear microscopy, and clinical findings, and consider repeat testing if suspicion is high.

Is fasting required for the Babesia cePCR test?

No. The test uses whole blood and does not require fasting.

Why does this test take longer than standard PCR?

The culture-enhancement step requires incubation of the specimen for several days to amplify parasite numbers before extraction and amplification, extending the turnaround to 10–14 business days.

Should patients avoid antimicrobial therapy before the test?

Ideally, collect the specimen before starting antiprotozoal treatment, as therapy reduces parasite burden and can produce false-negative results. If the patient is already on treatment, note this on the requisition and interpret cautiously.

Does the test identify Babesia species?

Some laboratories report species identification, commonly B. microti in the northeastern and upper midwestern United States and B. duncani on the west coast. Consult the laboratory report for specificity; the assay primarily confirms presence or absence of Babesia DNA.

Who is at highest risk for severe babesiosis?

Asplenic, immunocompromised, and elderly patients are at risk for severe or fulminant babesiosis with high parasitaemia and haemolytic anaemia. These patients warrant early molecular and serological testing and aggressive treatment.

Should practitioners screen for co-infections when Babesia is detected?

Yes. Babesia is transmitted by the same tick vector as Borrelia burgdorferi (Lyme disease) and Anaplasma phagocytophilum, so co-infection is common. Order Lyme serology or PCR and Anaplasma testing in parallel when clinical context warrants.

BML-LYM-004lyme tick borneUSA

Babesia cePCR (Culture enhanced)

The Babesia cePCR test detects Babesia species DNA in whole blood after culture enhancement, increasing sensitivity for low or intermittent parasitaemia. Ordered for acute febrile illness with haemolysis, suspected tick-borne co-infection, or when serology is equivocal, it confirms active infection and guides antiprotozoal therapy in immunocompetent and high-risk patients.

Biomarkers

Blood (whole blood)

Sample

10–14 business days

Turnaround

Fasting

What is the Babesia cePCR test?

The Babesia cePCR test uses culture-enhanced polymerase chain reaction to detect Babesia species DNA in whole blood. Babesiosis is a tick-borne zoonosis that presents with fever, haemolytic anaemia, and constitutional symptoms ranging from mild to life-threatening, especially in asplenic, elderly, or immunosuppressed patients. Many cases are asymptomatic or paucisymptomatic and resolve without recognition, but chronic or relapsing symptoms can mimic other tick-borne co-infections. Culture enhancement distinguishes this assay from standard PCR: whole blood is incubated under conditions that support parasite replication, amplifying parasite numbers before nucleic-acid extraction and PCR. This increases sensitivity during the early acute phase when parasitaemia is low or oscillating, and in patients with persistent low-grade infection. Practitioners order cePCR when serological tests are indeterminate, when direct microscopy is negative despite clinical suspicion, or when confirmation of active infection is needed to guide therapy.

What does the Babesia cePCR test measure?

Babesia cePCR(Babesia species DNA by culture-enhanced PCR)

Range: Not detected.Optimal: Not detected.Detected/Not Detected

Babesia are intraerythrocytic protozoan parasites transmitted by ixodid ticks, primarily Ixodes scapularis in North America. The organisms invade and multiply within red blood cells, producing a haemolytic infection. Parasitaemia is often transient and low-grade in immunocompetent hosts but can be substantial in asplenic or immunocompromised patients. Standard PCR detection is limited by low or intermittent blood parasitaemia; culture-enhanced PCR addresses this by incubating whole blood to amplify parasite numbers before nucleic-acid extraction, increasing analytical sensitivity for early or subclinical infection.

Detection of Babesia DNA by cePCR confirms active or recent infection when serological tests are equivocal or when direct visualisation on blood smear is negative. The culture-enhancement step makes the assay more sensitive than conventional single-time-point PCR, particularly in patients with low parasitaemia or those who have received partial antimicrobial therapy. A positive result supports the diagnosis of babesiosis and guides antiprotozoal treatment; a negative result does not exclude infection if suspicion remains high, and correlation with serology and clinical findings is essential.

Why is the Babesia cePCR test ordered?

Evaluation of acute febrile illness with haemolytic anaemia, thrombocytopaenia, or elevated transaminases following tick exposure in endemic areas
Patients with documented or suspected Lyme disease who have persistent or relapsing symptoms that may represent Babesia co-infection
Asplenic or immunocompromised patients with fever and constitutional symptoms after potential tick exposure, where babesiosis can be severe
Investigation of unexplained anaemia or haemolysis in an individual with outdoor or travel history to tick-endemic regions
Confirmation of active infection when Babesia serology (IgM or IgG) is equivocal or when distinguishing past from current infection is clinically important
Screening blood or organ donors with high-risk exposure, particularly those from endemic areas or with a history of confirmed babesiosis
Monitoring parasite clearance in treated patients with severe or persistent babesiosis, where persistent DNA detection may indicate treatment failure or relapse

Sample collection and turnaround

Sample type

Blood (whole blood)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

10–14 business days

Collection notes

Phlebotomy required; whole blood collected in EDTA (lavender-top) tube. The specimen must be shipped to IgeneX according to their transport requirements — typically ambient or refrigerated, never frozen, to preserve parasite viability for culture. Consult the laboratory's collection kit and instructions for exact handling, as the culture-enhancement step depends on viable organisms.

Specimen requirements

Whole blood in EDTA anticoagulant, typically 5–10 mL. Ship according to IgeneX instructions; do not freeze. Specimens are cultured in-house before nucleic-acid extraction and PCR amplification.

What can affect Babesia cePCR results?

reducesAntimicrobial therapy

Antiprotozoal treatment (atovaquone plus azithromycin or clindamycin plus quinine) reduces parasite burden, lowering DNA yield; test before therapy when feasible, or recognise that a negative result during or after treatment does not exclude prior infection.

variableTiming of specimen collection relative to symptom onset

Parasitaemia fluctuates and peaks during the acute phase; very early or late convalescent samples may miss the window of detectable DNA despite culture enhancement.

variableSpecimen handling and transport conditions

Whole-blood specimens must be transported and stored under conditions that preserve parasite viability for culture; prolonged storage or temperature extremes can reduce organism recovery and assay sensitivity.

variableLow-grade or intermittent parasitaemia

Even with culture enhancement, extremely low or cyclical parasite levels can produce false-negative results; clinical context and serological correlation are necessary.

variableCo-infection with Borrelia or Anaplasma

Tick-borne co-infections are common and can modulate immune response and clinical presentation, complicating interpretation; serological and molecular testing for other pathogens should be considered in parallel.

What do Babesia cePCR results mean?

Elevated

Not applicable — this is a qualitative molecular test reporting detected or not detected.

Normal

Not detected. A negative result indicates no Babesia DNA was amplified after culture enhancement. This result does not exclude babesiosis if the specimen was collected very early or late in the illness, during or after antimicrobial therapy, or if parasitaemia is below the assay's detection threshold. Correlate with serology (IgM and IgG by immunofluorescence or immunoblot), blood-smear microscopy if parasitaemia is high enough to visualise, and clinical findings. In patients with high clinical suspicion, repeat testing or adjunctive serology is warranted.

Reduced

Not applicable.

Note: Detected. Babesia DNA is present, confirming active or recent infection. The assay does not quantify parasite load or differentiate Babesia species in all cases, though some laboratories report species identification (commonly B. microti in the northeastern and upper midwestern United States, B. duncani on the west coast). A positive cePCR supports the diagnosis and indicates the need for antiprotozoal therapy. Correlation with clinical presentation, haematological findings (haemolytic anaemia, thrombocytopaenia), and co-infection screening (Borrelia, Anaplasma, Ehrlichia) is essential. Persistent detection after standard therapy may indicate relapse or treatment failure and warrants prolonged or alternative regimens, particularly in immunocompromised or asplenic patients.

Frequently asked questions

Culture-enhanced PCR incubates whole blood to allow parasites to replicate before nucleic-acid extraction, amplifying parasite numbers and increasing sensitivity. Standard PCR tests the specimen as drawn, so it is less sensitive when parasitaemia is low or intermittent.

How to access the Babesia cePCR test

The Babesia cePCR reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Krause PJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. Clin Infect Dis. (2021)
Vannier EG, et al. Human babesiosis. Infect Dis Clin North Am. (2015)
Wormser GP, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines. Clin Infect Dis. (2006)
Leiby DA. Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin Microbiol Rev. (2011)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.